Navigation Links
Resisting the flu
Date:1/15/2014

McGill researchers, led by Dr. Maya Saleh of the Department of Medicine, have identified an enzyme, cIAP2 that helps the lungs protect themselves from the flu by giving them the ability to resist tissue damage. "It's a discovery that offers exciting new avenues for controlling influenza, since until now attempts to target the virus itself have proven challenging, especially in the face of emerging new strains of the virus," says Saleh, who is also a researcher at the Research Institute of the McGill University Health Centre (RI-MUHC). "The results from our study now suggest that one effective way of countering influenza infections may instead be offered by enhancing the body's resistance to the virus."

Like many other battles, fighting the flu is a combination of both control and defence. On the one hand, on the control end of the process, our immune system comes into play to prevent the virus from replicating inside our cells, and attacking with increasing strength. At the same time, on the defensive side, our bodies need to actively resist the destruction and harmful cell death that is caused by the virus.

By investigating the role played by cIAP2 in mice with the H1N1 influenza A virus, what Saleh and her team discovered was that the enzyme is necessary to control the nature of cell death during influenza infection. They found that cIAP2, which functions by modifying and activating survival factors in the cell, steers the body away from an inflammatory and auto-destructive process known as necrotic death. The enzyme is, in effect, a gatekeeper of cell death.

In its absence, the same factors that depend on cIAP2 to keep the cell alive, reveal a destructive side and induce a harmful form of cell death. cIAP2 therefore not only protects the infected cells from dying in such a manner, but also protects uninfected neighbouring cells in the same tissue. By doing so, this enzyme increases the resistance of the lung to influenza infection and associated pathology.

The researchers believe that the identification of this pathway of resistance to flu opens a number of avenues for future drug development. Ian Rodrigue-Gervais is a post-doctoral fellow in Prof. Saleh's lab and one of the authors on the paper. According to him, what is truly exciting about this discovery is that it suggests that it may be possible to suppress features of flu-inflicted tissue injury. "What we saw in this study is that if the enzyme cIAP2 is present, the host can better tolerate the infection and then reduce the illness."


'/>"/>
Contact: Katherine Gombay
katherine.gombay@mcgill.ca
McGill University
Source:Eurekalert  

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Resisting the flu
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... , Mar 24, 2017 Research ... Therapy Manufacturing Market, 2017-2027" report to their offering. ... The Cell ... the rapidly growing market of cell therapy manufacturing and focuses ... manufacturing facilities. These therapies are anticipated to emerge as viable ...
Breaking Medicine Technology: